IMHO, 100% wrong - but thanks for sharing.... i
Post# of 30028
Posted On: 10/19/2014 10:51:50 AM
IMHO, 100% wrong - but thanks for sharing....
interesting few months ahead - but have my eyes squarely fixed on Jan 12, 2015 - Jan 14, 2015 for revenue
03.) Lympro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
11.) MANF RP - Orphan Drug / poss. 30 day FDA apvl. 11/15 - (completed 10/16/14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
16.) PhenoGuard - JV Partnership update potential
17.) PhenoGuard - discovery of 2nd protein family
18.) PhenoGuard - transformed into 1st rationally designed NF discovery platform
19.) PhenoGuard - evaluation of external drug candidates for in-licensure potential
20.) NuroPro - preparing Ph. 2 CLIA validation study
21.) potential - financial engineering
22.) potential - multiple grant funding
23.) potential - new acquisition / Cerora AD scanner
24.) potential - diagnostics div. spin off
25.) NASDAQ uplisting - (est. 4Q14)
Read More: http://investorshangout.com/post/view?id=2145...z3GbSztxqu
interesting few months ahead - but have my eyes squarely fixed on Jan 12, 2015 - Jan 14, 2015 for revenue
03.) Lympro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
11.) MANF RP - Orphan Drug / poss. 30 day FDA apvl. 11/15 - (completed 10/16/14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
16.) PhenoGuard - JV Partnership update potential
17.) PhenoGuard - discovery of 2nd protein family
18.) PhenoGuard - transformed into 1st rationally designed NF discovery platform
19.) PhenoGuard - evaluation of external drug candidates for in-licensure potential
20.) NuroPro - preparing Ph. 2 CLIA validation study
21.) potential - financial engineering
22.) potential - multiple grant funding
23.) potential - new acquisition / Cerora AD scanner
24.) potential - diagnostics div. spin off
25.) NASDAQ uplisting - (est. 4Q14)
Read More: http://investorshangout.com/post/view?id=2145...z3GbSztxqu
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼